L. Golden

Increasing Colorectal Cancer Screening at Community-Based Primary Care Clinics in San Francisco.

R. Marx, Winnie M Tse, L. Golden, 2016, Journal of public health management and practice : JPHMP.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Suzanne F. Jones, R. Kurzrock, F. Janku, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

R. Wenham, I. Vergote, J. Fiorica, 2019, Gynecologic oncology.

Early COVID‐19 Successes in Skilled Nursing Facilities in San Francisco

S. Philip, J. Louie, T. Aragón, 2020, Journal of the American Geriatrics Society.

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2018, Clinical Cancer Research.

Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2015 .